Singapore, Nov. 4 -- 4D Molecular Therapeutics has announced a strategic partnership with Otsuka Pharmaceutical to develop and commercialise 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) in the greater Asia-Pacific (APAC) region including Japan.

The strategic partnership combines 4DMT's expertise in AAV genetic medicine, development in retina and manufacturing with Otsuka's strong development expertise, regulatory experience and commercial infrastructure across APAC markets. Together, the companies aim to receive 4D-150 marketing approval and commercialisation in major markets globally. 4D-150 is a potentially transformative backbone therapy providing durable benefit in retina...